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Abstract
Introduction: The role of glucocorticoids in atherosclerosis development is not clearly established. Human studies show a
clear association between glucocorticoid excess and cardiovascular disease, whereas most animal models indicate an
inhibitory effect of glucocorticoids on atherosclerosis development. These animal models, however, neither reflect long-
term glucocorticoid overexposure nor display human-like lipoprotein metabolism.
Aim: To investigate the effects of transient and continuous glucocorticoid excess on atherosclerosis development in a
mouse model with human-like lipoprotein metabolism upon feeding a Western-type diet.
Methods: Pair-housed female APOE*3-Leiden.CETP (E3L.CETP) mice fed a Western-type containing 0.1% cholesterol for 20
weeks were given corticosterone (50 mg/ml) for either 5 (transient group) or 17 weeks (continuous group), or vehicle
(control group) in the drinking water. At the end of the study, atherosclerosis severity, lesion area in the aortic root, the
number of monocytes adhering to the endothelial wall and macrophage content of the plaque were measured.
Results: Corticosterone treatment increased body weight and food intake for the duration of the treatment and increased
gonadal and subcutaneous white adipose tissue weight in transient group by +35% and +31%, and in the continuous group
by +140% and 110%. Strikingly, both transient and continuous corticosterone treatment decreased total atherosclerotic
lesion area by 239% without lowering plasma cholesterol levels. In addition, there was a decrease of 256% in macrophage
content of the plaque with continuous corticosterone treatment, and a similar trend was present with the transient
treatment.
Conclusion: Increased corticosterone exposure in mice with human-like lipoprotein metabolism has beneficial, long-lasting
effects on atherosclerosis, but negatively affects body fat distribution by promoting fat accumulation in the long-term. This
indicates that the increased atherosclerosis observed in humans in states of glucocorticoid excess may not be related to
cortisol per se, but might be the result of complex indirect effects of cortisol.
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Introduction
Atherosclerosis develops as a result of a chronic inflammatory
response in an injured vessel wall [1], which is preceded by
accumulation of leukocytes and fat deposition, leading to plaque
formation [2]. The initial mechanisms in atherogenesis, however,
are still incompletely understood.
The role of glucocorticoids (GC) in the development of
atherosclerosis is not yet clearly established in humans or in
animals and is, at least, dependent on individual’s [3,4] or animal’s
[5] exposure to appropriate levels of adrenal steroids. Human data
show an association between increased GC secretion and
cardiovascular disease even after long-term successful correction
of GC excess [6], whereas previous studies in animals, e.g. rabbits
[7,8,9,10,11] and dogs [12] using either natural or synthetic GC,
suggest an atheroprotective role of GC. On the other hand, 11b-
dehydrogenase type 2 (11bHSD2) deficient mice, in which the
activation of the mineralocorticoid receptor (MR) by GCs cannot
be prevented, have an increased atherosclerotic plaque develop-
ment [13], suggesting that increased activation of the MR
promotes atherosclerotic plaque formation. However, a recent
study demonstrated that adrenalectomy, which removes endoge-
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nous GC, stimulated the formation of initial atherosclerotic lesions
in low-density-lipoprotein receptor knockout mice [5].
Only a limited number of studies have evaluated the effect of
endogenous GC excess on atherosclerosis development in mice.
These studies, that used chronic stress to increase endogenous GC,
reported either an increase [14,15] or no effect [16] on
atherosclerosis development in ApoE-deficient mice. However,
chronic stress, in addition to increasing GC, induces other
complex endocrine and metabolic changes, for instance increased
sympathetic outflow [17] that may affect atherosclerosis develop-
ment. These mouse models therefore do not reflect long-term
endogenous GC overexposure, like in Cushing’s syndrome (CS) in
humans. Furthermore, ApoE-deficient mice do not reflect human-
like lipoprotein metabolism and have a deviant immune status
compared to wild-type mice [18].
In the present study, our aim was to investigate the effects of GC
excess on atherosclerosis development in the APOE*3-Leiden.-
CETP (E3L.CETP) mouse, a well-established model for human-
like lipoprotein metabolism that is prone to develop atherosclerosis
upon feeding a cholesterol-containing Western-type diet [19] and
is responsive to the hypolipidemic drugs used in the clinic similar
to humans [20–23] The latter is in sheer contrast to other mouse
models for hyperlipidemia and atherosclerosis including apoE-
knockout and LDL receptor-knockout mice. We administered
corticosterone (CORT) non-invasively via the drinking water, and
based on the clinical observation in CS patients, we investigated
both transient and chronic effects of CORT on atherosclerosis
development.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
regulations of Dutch law on animal welfare, and the institutional
ethics committee for animal procedures of Leiden University. The
protocol was approved by the institutional ethics committee for
animal procedures of Leiden University (Permit Number: 10132
and for the pilot experiment: 08221) and all efforts were made to
minimize suffering.
Mice, Housing, Corticosterone Supplementation, and
Diets
Human CETP expressing transgenic mice, which express
CETP under control of its natural flanking regions, were crossbred
in our own animal facility with E3L mice to obtain the
heterozygous E3L.CETP mice on a C57Bl/6 background [24].
Female mice (10–16 weeks of age) were pair housed and
maintained on a 12 h:12 h light-dark cycle (lights on 7 a.m.) in
a climate controlled environment, with ad libitum access to food
and drinking water. Mice were fed a Western-type diet containing
0.1% cholesterol (Diet T +0.1% cholesterol, Arie Blok Diervoed-
ing, Woerden, the Netherlands) for a period of three weeks after
which they were matched for age, plasma cholesterol, triglycerides,
phospholipids, age and bodyweight and then randomized to
receive CORT (Sigma-Aldrich, Manchester, UK) at a concentra-
tion of 50 mg/ml in the drinking water with 0.25% ethanol as
vehicle for five weeks (transient group, n = 17), continuously for the
entire duration of the experiment (seventeen weeks) (continuous
group, n = 21), or vehicle (control group, n = 19). Food and
bodyweight were recorded weekly. At the end of the experiment
mice were decapitated within 90 seconds from disturbing the cage
and trunk blood was collected. Gonadal and subcutaneous fat pads
were removed from each mouse by the same person to reduce
inter-observer variation. The same area of subcutaneous fat was
removed from each mouse excluding the inguinal lymph node. Fat
pads and adrenals were weighed using a micro scale, and frozen in
liquid nitrogen.
Pilot Experiment for the Determination of Optimal CORT
Dose
Prior to experiment, we performed a dose finding study in male
C57Bl/6J mice fed HFD with 12.5 mg/ml (n = 2), 25 mg/ml
(n = 4) and 50 mg/ml (n = 2) of CORT, and control receiving
0.25% ethanol (n = 2) as vehicle for four weeks to determine the
optimal CORT dose. These dosages were chosen based upon a
previous study [25] that documented profound metabolic effects
with CORT 100 mg/ml and less pronounced effects with 25 mg/
ml. Based upon our dose finding study, we chose 50 mg/ml
CORT in the drinking water for our subsequent experiments as
this dose led to the largest increases in food intake and body weight
as well as in plasma cholesterol. Because male mice do not readily
develop atherosclerosis and the known models are in majority
female models, we used female mice for the purpose to study the
atherosclerosis development. In males and females, this CORT
dose was sufficient to increase food intake and to maintain a higher
bodyweight throughout the experiment. In addition, circulating
circadian CORT levels at week 5 were 5–8 fold increased in the
morning and 3–4 fold in the evening (data not shown).
Sampling of Circadian Corticosterone, Hormone, and
Lipid Measurements
Plasma CORT was sampled before CORT administration
(baseline), and after CORT administration at week 5 during the
first light hour at 07.00 h, at 12.00 h, during the last light hour at
18.00 h, and three hours after the onset of the dark phase at
22.00 h. During the dark phase samples were collected in red light
conditions. All CORT samples were obtained within 90 seconds
from disturbing the cage, via tail incision, allowing the mouse to
move freely on top of the home cage [26]. Trunk blood was used
to determine plasma CORT at the end of the experiment after
CORT administration at week 17 at 09.00 h and 18.00 h. Total
plasma cholesterol, triglycerides, phospholipids, insulin and
glucose were sampled after 4 hour-fast at baseline, week 5, 8
and 17 of the intervention. Body weight and food intake were
measured weekly.
Plasma CORT levels were determined by radioimmunoassay
(MP Biomedicals LCC, Orangeburg, NY). Plasma levels of total
cholesterol, triglycerides and non-esterified free fatty acids were
measured with enzymatic colorimetric reaction (Roche diagnostics
GmbH, Mannheim; and Wako Pure Chemical Industries,
respectively), plasma insulin was measured with an ELISA (Crystal
Chem Inc., Downers Grove, IL, USA) and plasma glucose with a
hexokinase method (Instruchemie, Delfzijl, The Netherlands).
Homeostasis model index of insulin (HOMA-IR) was calculated by
multiplying fasting insulin concentration (mU/ml) with fasting
glucose (mmol/l), and dividing with 22.5 [27].
Lipoprotein Profiling
Distribution of cholesterol over plasma lipoproteins was
determined using fast protein liquid chromatography. Pooled
plasma from each group were used and 50 ml of each pool was
injected onto a Superpose 6 PC 3.2/30 column (A¨kta System,
Amersham Pharmacia Biotech, Piscataway, NJ) and eluted at a
constant rate of 50 ml/min in PBS, 1 mM EDTA, pH 7.4.
Fraction were collected and assayed for cholesterol as described
above.
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Gene Expression Analysis in Adipose Tissue
Total RNA was extracted from gonadal fat pads using the
Nucleospin RNA II kit (Macherey-Nagel, Duren, Germany)
according to manufacturer’s instructions. RNA quality of each
sample was examined by the lab-on-a-chip method using Experion
Std Sens analysis kit (Biorad, Hercules, CA) and RNA concen-
tration of each sample was determined by Nanodrop technology
(Thermo Scientific, Wilmington, USA). Then, total RNA was
reverse-transcribed with iScript cDNA synthesis kit (1708891, Bio-
Rad), and obtained cDNA was purified with Nucleospin Extract II
kit (636973, Macherey-Nagel, Bioke´). Real-time qPCR was
performed on a CFX96 machine (Bio-Rad), the reaction mixture
consisting of SYBR-Green Sensimix (QT615, GC Biotech),
cDNA, primers (Biolegio, Nijmegen, The Netherlands), and
nuclease-free water in a total reaction volume of 10 ml. mRNA
values of each gene were normalized to mRNA levels of ß2-
microglobulin (ß2m) and hypoxanthine ribosyltransferase (Hprt).
Primer sequences are listed in Table S1.
Quantification of Atherosclerosis
After 17 weeks of intervention, mice were killed by decapitation
and the hearts were isolated. Hearts were fixed in phosphate-
buffered 4% formaldehyde, dehydrated and embedded in paraffin.
Cross-sections (5 mm) throughout the aortic root area were cut. 12
sections per mouse, stained with hematoxylin-phloxin-saffron for
histological analysis, with 50 mm-intervals were used for athero-
sclerosis measurements. Lesions were categorized for severity
according to the guidelines of the American Heart Association,
adapted for mice [28,29], as follows: type 0 (no lesions), types 1
through 3 (early fatty streak-like lesions containing foam cells), and
type 4 to 5 (advanced lesions containing foam cells in the media,
presence of fibrosis, cholesterol clefts, mineralization, and/or
necrosis). AIA 31240 antiserum (1:3000, Accurate Chemical and
Scientific, Westbury, NY) was used to quantify macrophage
content of the plaque as well as monocytes adhering to the
endothelium. Lesion area, the macrophage area and the number
of monocytes adhering to the endothelium were quantified using
Image J software (National Institutes of Health).
Serum Macrophage Colony-stimulating Factor (M-CSF)
and Anti-oxidized Low-density Lipoprotein (ox-LDL)
Antibodies Measurements
Macrophage colony-stimulating factor (M-CSF) was measured
using a mouse M-CSF Quantikine ELISA kit according to the
manufacturer’s instructions (MMC00, R&D Systems Inc, Ger-
many). An EIA/RIA high binding 96-well Costar plate (Corning
Inc., Corning, NY, USA) was coated with ox-LDL (7.5 mg/mL) in
PBS. IgM and IgG2a antibodies against oxLDL in serum were
measured using an ELISA Ig detection kit (Zymed Laboratories,
San Francisco, CA, USA) according to the manufacturer’s
protocol.
Statistical Analysis
Data are presented as means 6 SEM. Statistical differences
were calculated using Anova with Tukey’s post-hoc test, for
multiple comparisons, except for plasma CORT measurements
transient and continuous groups were compared with the control
group individually per time point using an unpaired two tailed T-
test, with GraphPad Prism, version 5.01. P,0.05 was considered
as statistically significant.
Results
CORT Treatment Increases Plasma CORT Concentrations
and Affects Circadian Rhythm
Chronic administration of high doses of CORT in the drinking
water (50 mg/ml) resulted in significant increases in plasma
CORT levels at week 5 (Fig. 1B) in both groups, compared to
controls (transient group: 07.00 h 8-fold, 12.00 h 3-fold, 18.00 h
1-fold and 22.00 h 4-fold; continuous group: 07.00 h 5-fold,
12.00 h 4-fold, 18.00 h 1-fold and 22.00 h 3-fold). At week 17
(Fig. 1C) there were no differences between groups at 09.00 h and
18.00 h. At the end of the experiment, thymus weight (Fig. 1D)
was not different between the three groups but adrenal weight
(Fig. 1E) was significantly reduced in the continuously exposed
group by 250%, in agreement with adrenal atrophy secondary to
long-term exogenous GC exposure.
CORT Treatment Affects Food Intake and Bodyweight
and Induces Long-lasting Changes in Body Composition
and Inflammation in Adipose Tissue
As expected, CORT treatment increased food intake of the
transient and the continuous group during the first three weeks of
the experiment after which the transient group returned to the
level of the controls and food intake with continuous treatment
remained elevated (Fig. 2A). This increase was accompanied by an
increase in body weight (Fig. 2B) in both groups. After the
discontinuation of CORT treatment, body weight decreased to the
level of the controls. The continuously exposed group showed a
continuous increase in body weight and maintained a higher body
weight to the end of the experiment (Fig. 2B) compared to the
other two groups. After 17 weeks, gonadal and subcutaneous fat
pad weights (Fig. 2C and D), when compared to controls, were
significantly increased by +35% and +31%, respectively, in the
transient group, and by +140% and +110% in the continuous
group. To evaluate whether the increased fat mass resulted in
changes of inflammation in the fat pad, the mRNA expression of
markers of the macrophage content (i.e. F4/80 and Cd68) and
proinflammatory cytokines [Tumor necrosis factor a (Tnfa) and
Interleukin-6 (Il-6)] in the gonadal fat pad were determined. As
compared to control group, transient administration of CORT did
not affect the expression of F4/80 (Fig. 2E) and CD68 (Fig. 2F), but
decreased the expression levels of Tnfa (Fig. 2G) and Il-6 (Fig. 2H)
in the long-term by 232% and 247%, respectively; while
continuous administration of CORT increased the expression of
F4/80 (Fig. 2E) and CD68 (Fig. 2F) by +58% and +70%,
respectively, decreased the expression of Tnfa (Fig. 2G) by 226%
and did not affect the expression of Il-6 (Fig. 2H). These data
indicate although excess GC exposure increased fat mass, which
was accompanied with an increase in macrophage content,
expression of proinflammatory cytokines in the adipose tissue
was generally reduced.
CORT Treatment does not Affect Plasma Lipids,
Cholesterol Lipoprotein Profile, but Increases Plasma
Insulin and HOMA-IR
Although both transient and continuous administration of
CORT increased food intake to a certain extent, CORT
treatment did not increase plasma levels of total cholesterol,
triglycerides or phospholipids during the experimental period of 17
weeks (Table 1). Moreover, there were no differences between
groups in the distribution of cholesterol over lipoproteins (Fig. 3A–
C). Plasma levels of insulin and HOMA-IR, but not plasma
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glucose levels, were increased (Fig. 3 D–F) in the continuous group
at week 17, reflecting GC-induced insulin resistance.
Transient and Continuous CORT Treatment Decrease
Atherosclerosis Lesion Area to a Similar Extent
Remarkably, CORT treatment decreased total atherosclerotic
lesion area equivalently in both transiently (239%) and contin-
uously (239%) treated groups (Fig. 4A and B). Moreover, both
transient and continuous groups showed similar trends towards a
less severe lesion phenotype as compared to the control group
(Fig. 4C), suggesting that CORT treatment reduces atherosclerosis
development in a long-lasting manner. CORT treatment, neither
transiently nor continuously, affected the number of monocytes
adhering to endothelium wall (Fig. 4D and E), yet continuous
administration of CORT did reduce the macrophage content
(256%) of the plaque (Fig. 4D and F) as well as the macrophage
content as percentage of the total plaque area (252%) (Fig. 4G). A
reduction of the macrophage content of the plaque (227%,
P= 0.125) and percentage macrophages in total plaque area
(227%, P= 0.145) was observed in the transient group and but
these reductions failed to reach statistical significance (Fig. 4F and
G). Since uptake of oxidized LDL (ox-LDL) by macrophages to
become foam cell plays an important role in the development and
progression of atherosclerosis, we measured specific antibodies
against ox-LDL in the circulation. As compared to control group,
CORT treatment, neither transiently nor continuously, influenced
the ox-LDL specific IgG2a and IgM level, indicating that CORT
probably does not affect the ox-LDL level in circulation (Fig. 4H).
Because macrophage proliferation and differentiation were shown
to be linked to the atherosclerotic process [1], an essential factor
regulating macrophage growth, macrophage colony stimulation
factor (M-CSF) [30] was measured at the end of this experiment.
However, no differences in the serum levels of M-CSF were
detected among groups (Fig. 4I).
Discussion
This study demonstrates for the first time that CORT treatment
resulting in increased plasma CORT concentrations decreases
atherosclerotic plaque formation in mice with human-like
lipoprotein metabolism, without affecting either plasma lipid levels
or lipoprotein profiles. Interestingly, inhibition of atherogenesis
was found both in transiently and continuously exposed animals,
whereas continuous treatment with CORT also decreased
macrophage content of the plaque despite the normalization of
the body weight. In addition, CORT treatment resulted in long-
lasting changes in body fat content, which were still present even
12 weeks after abrogation of CORT. This indicates that increased
CORT exposure per se has beneficial, long-lasting effects on
atherosclerosis, but negatively affects body fat distribution and
insulin sensitivity, by promoting fat accumulation in the long-term.
Figure 1. Effect of transient and continuous CORT treatment on circadian plasma CORT levels in female E3L.CETP mice at baseline
(A), week 5 (B) and week 17 (C), as well as on thymus weight (D) and adrenal weight (E) at week 17 (Control group: white bars,
transient group: grey bars and continuous group: black bars). Data are means 6 SEM (n = 17–21), *, #P,0.05, **, ##P,0.01, ###P,0.0001,
*versus control group and #transient group.
doi:10.1371/journal.pone.0063882.g001
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The concentration of glucocorticoids (GCs) attained in our
experiments is higher than under stress state but well comparable
to patients with severe Cushing’s syndrome, where cortisol
secretion was 7 times higher that in healthy controls and
circulation cortisol concentrations was 3–5 times higher [31].
Increased plasma CORT levels were easily induced non-
invasively using CORT in the drinking water. CORT affected
circadian GC rhythm by reducing the degree of variation in
plasma concentrations. The human clinical equivalent of chronic
hypercortisolemia, Cushing’s syndrome (CS), is characterized by a
blunted or even complete loss of diurnal rhythm [3]. In our model
we re-capitulate some of these key temporal aspects of CS:
although a chronic high circulating cortisol levels is a key aspect of
CS, the most reliable measure for diagnosis is very high late night
(i.e. 22:00–24:00 h) plasma cortisol [3]. Our high- CORT animals
parallel these aspects of the syndrome, with both high baseline
levels of CORT (200 ng/ml), as well as a peak in CORT at the
end of the night (rather than at the beginning). Moreover, the
continuously exposed group displayed reduced adrenal sizes, in
agreement with adrenal atrophy, secondary to the long-term
exogenous CORT administration despite normal plasma CORT
levels found at the end of the experiment. This might be explained
by increased metabolism of CORT as well as by other
pharmacokinetic adaptations like increased clearance and in-
creased distribution volume as a result of increased adipose tissue.
Plasma lipid levels were not affected by transient nor continuous
CORT treatment. This is interesting particularly in the case of
plasma values of total cholesterol, VLDL-cholesterol and VLDL-
triglycerides since these are well known risk factors for the
development of atherosclerosis. In fact, cholesterol exposure
generally is a good predictor of atherosclerosis development in
E3L.CETP mice (Princen and Rensen, unpublished observations).
Moreover, CORT exposure did not affect lipoprotein profiles. In
previous studies, mice were subjected to chronic stress, which
causes a complex of endocrine changes, including high CORT
levels. These studies have reported inconsistent effects on plasma
cholesterol levels, which were increased [15], decreased [16], or
not reported [14]. These studies used ApoE-deficient mice in
which the ApoE- deficiency causes severe accumulation of
cholesterol in macrophages resulting in a high pro-inflammatory
state, which could explain the differences observed in atheroscle-
rosis development between our low grade inflammation model of
E3L.CETP mice fed a low amount of dietary cholesterol (twice
human daily intake) [32,33]. In addition, the use of chronic stress
to increase endogenous GCs in previous models will also induce
other complex endocrine and metabolic changes [17] that may
Figure 2. Effect of transient and continuous CORT treatment on food intake (A), body weight (B) (Control group: white circles,
transient group: grey squares and continuous group: black triangles), gonadal fat (C) and subcutaneous fat (D) as % of the body
weight, mRNA expression of F4/80 (E), CD68 (F), Tnfa (G) and Il-6 (H) in the gonadal fat (Control group: white bars, transient group:
grey bars and continuous group: black bars). Data are means6SEM (n= 17–21), Anova with Tukey’s post-hoc test, *, #P,0.05, **, ##P,0.01,
***, ###P,0.001, *versus control group and #versus transient group.
doi:10.1371/journal.pone.0063882.g002
Figure 3. Effect of transient and continuous CORT treatment on cholesterol distribution over lipoproteins fractioned by FPLC at
baseline (A), week 5 (B) and 17 (C) (Control group: white circles, transient group: grey squares and continuous group: black
triangles) and on plasma insulin (D), plasma glucose (E), HOMA-IR (F), (Control group: white bars, transient group: grey bars and
continuous group: black bars) on week 17. Data are means 6 SEM (n= 17–21), Anova with Tukey’s post-hoc test, **, ###P,0.001, *versus
control group and #versus transient group.
doi:10.1371/journal.pone.0063882.g003
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also affect atherosclerosis development. Humans with high GCs
also have inconsistent cholesterol levels. In the literature, the
prevalence of hyperlipidemia in patients with CS varies from 38%
to 71% [34]. A study by Mancini et al (2004) has shown that
hyperlipidemia occurs less frequently than the other metabolic
complications of CS and that it was not correlated to the degree of
hypercortisolism or duration of the disease [35]. However, the
causative role of cortisol excess for hyperlipidemia has not been
extensively described in the literature and the findings are, like the
animal data, controversial. In some study populations, the
prevalence of hypertriglyceridemia was even lower than in BMI-
matched controls [36].
Intriguingly, CORT treatment reduced atherosclerotic lesion
area, and tended to decrease lesion severity, to a similar extent in
transiently vs continuously exposed mice. This suggests that GCs
are able to induce long-term effects in the preliminary processes of
atherosclerotic plaque formation. It is tempting to speculate on
possible underlying mechanistic explanations for this phenome-
non. One possibility is the induction by increased GC exposure of
epigenetic mechanisms, like chromatin remodeling and histone
modifications [37]. These alterations have been demonstrated in
the context of chronic CORT [38], and may lead to long lasting
suppression of or changes in macrophage function. Extensive
documentation supports a crucial role for macrophages in the
initiation of atherosclerosis by entering the vessel wall, taking up
oxidized LDL (ox-LDL) [1,2] and transforming into foam cells
that produce a variety of cytokines further driving the process of
the plaque formation, as well as macrophage proliferation and
differentiation [39,40]. In the present study, transient and
continuous CORT treatment did not affect the plasma ox-LDL
level, albeit that continuous CORT treatment significantly
reduced the macrophage content of the plaque, and a similar
trend was also observed in the transiently exposed group. GCs
were shown to decrease the development of atherosclerosis by
reducing the monocyte recruitment [41–43], macrophage foam
cell formation [44], macrophage growth, as well as macrophage
inflammatory action to produce pro-inflammatory cytokines [45].
In this study, no differences were observed in the number of
monocytes adhering to endothelium between the groups. It is
plausible that GCs excess inhibits macrophage growth instead of
monocyte recruitment as GCs inhibit macrophage colony
stimulating factor (M-CSF)-induced macrophage differentiation
in vitro [45]. Although, we did not detect any differences in serum
M-CSF level between groups, it should be realized that M-CSF is
a general marker for macrophage growth, and the systemic
concentration in plasma may not reflect the local macrophage
growth in the vessel. Additionally, GCs can also inhibit
macrophage growth by suppressing the granulocyte/macrophage
colony-stimulating factor (GM-CSF) production in isolated mac-
rophages [46], confirming that GCs might target the macrophage,
the major cellular CORT target, thereby attenuating macrophage
proliferation and differentiation, and thus inhibiting atheroscle-
rotic plaque formation.
In humans, increased GC exposure, like in patients with CS, is
associated with the metabolic syndrome and cardiovascular
disease, even after long-term successful correction of GC excess
[6,47,48]. Carotid intima media thickness (IMT) is increased and
vessel wall plaques are more common in patients with CS
[36,49,50]. Indeed, CS patients have abnormal fat distribution
and suffer from disturbed coagulation and osteoporosis. Although,
it is documented that bone mineral density fully recovers after
normalization of cortisol levels, other features, like the adverse
metabolic profile and the hypercoagulable state, do not completely
resolve [51,52]. The causal relation, however, between the episode
of cortisol overexposure and long-term changes in the develop-
ment of cardiovascular diseases is not established and is difficult to
assess in humans because of the rarity and heterogeneity of CS. In
agreement, in our mouse model CORT also stimulated the
development of other components of the metabolic syndrome. We
observed that CORT increased food intake, body weight, insulin
concentrations, and altered body composition. High CORT levels
are known to stimulate voluntary food intake dose-dependently
[53–55]. GCs are also known to induce insulin resistance [48].
Moreover, insulin and CORT synergistically promote redistribu-
tion of energy storage in favor of increased fat tissue [56]. The
changes in body weight were accompanied by a significant
increase in both gonadal and subcutaneous fat mass in continuous
group and, remarkably after 12 weeks of wash out, in transiently
exposed group as well. Chronically administered GC facilitates an
increase of fat mass in mice [25,57]. In humans, increased
exposure to cortisol (being either endogenous CS or exogenous
corticosteroids) induces increased total body fat [58], and is
specifically characterized by a redistribution of adipose tissue from
peripheral to central sites of the body, mainly in the truncal region
and visceral depots [59]. This is accompanied by a greater than
two-fold increased risk in insulin resistance/diabetes, hypertension,
and hyperlipidemia [39]. In the human equivalent of severe
chronic stress, CS, the prevalence of the metabolic syndrome is
increased [47,48], and intriguingly, after remission, these patients
still have increased waist circumference [36,60] and higher visceral
fat mass without an effect on the body mass index [61], and their
cardiovascular risk remains increased.
Adipose tissue macrophages are the primary source of the
proinflammatory cytokines, and the macrophage content of
adipose tissue has been shown to correlate positively with adiposity
[62]. In the present study, although excess GC exposure increased
fat mass and induced obesity, which was accompanied with an
increase in macrophage content, inflammation in the adipose
Table 1. Effect of CORT treatment on fasting plasma lipids.
Total cholesterol (mmol/) Triglycerides (mmol/l) Phospholipids (mmol/l)
Week Control Transient Continuous Control Transient Continuous Control Transient Continuous
0 10.061.5 10.262.3 10.262.1 3.961.1 4.361.1 4.161.4 3.660.4 3.760.6 3.560.6
5 13.261.8 14.065.2 14.864.2 4.661.6 4.862.3 4.561.6 4.560.6 4.561.1 4.661.0
8 13.462.0 13.763.9 12.464.3 3.861.5 4.061.7 4.260.9 4.560.5 4.660.8 4.260.9
17 12.462.8 10.263.2 10.063.0 3.261.4 3.361.0 2.960.5 3.860.9 3.460.9 3.460.7
Effect of transient and continuous CORT treatment on fasting plasma total cholesterol, triglycerides and phospholipids. Data are means 6 SEM (n = 17–21), Anova with
Tukey’s post-hoc test.
doi:10.1371/journal.pone.0063882.t001
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tissue was not elevated. Moreover, after abrogation of CORT
treatment, the macrophage content in the adipose tissue was
normalized and the reduction of inflammation was persisted in the
long-term despite of the presence of a persistent increase in fat
mass. CORT treatment induces prolonged, complex changes in
the adipose tissue that reflect both the adverse metabolic effects of
glucocorticoids by increasing the adiposity, and the anti-inflam-
matory capacity by reducing the expression of the proinflamma-
tory molecules in the macrophages. Therefore, we cannot exclude
that the protective effects of CORT treatment on atherosclerosis
development can, at least partly, be explained by decreased release
of cytokines from adipose tissue. It is well possible that at high
dose, the anti-inflammatory effects of GCs attenuate potentially
adverse metabolic influences. In clinical practice, this means that
GC schemes as used for anti-inflammatory indications might
benefit from adjustments towards a higher dose for a shorter
period of time (or even as a few ‘high dose ‘pulses’ as is used in
clinical practice with methyprednisolone instead of lower dosages
for a prolonged period of time.
In conclusion, increased CORT exposure in mice with a human
like lipoprotein metabolism has beneficial, long-lasting effects on
atherosclerosis, despite negatively affecting body fat distribution
and insulin sensitivity by promoting fat accumulation in the long
term. This indicates that the increased atherosclerosis observed in
the human in states of GC excess may not be related to cortisol per
se, but may be the result of complex effects of cortisol on the
endothelium and/or coagulation. The effects of GC excess,
therefore, are multiple, and dependent on many factors, but
above all, may irreversibly affect many pathophysiological
processes, thereby influencing long-term cardiovascular risk.
Supporting Information
Table S1 Primer sequences used for RT-qPCR.
(DOC)
Author Contributions
Conceived and designed the experiments: HEA YW HP PCNR AMP.
Performed the experiments: HEA YW. Analyzed the data: HEA YW.
Contributed reagents/materials/analysis tools: HEA YW. Wrote the
paper: HEA YW HP JAR LMH JWAS OCM NRB PCNR AMP.
References
1. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s.
Nature 362: 801–809.
2. McNeill E, Channon KM, Greaves DR (2010) Inflammatory cell recruitment in
cardiovascular disease: murine models and potential clinical applications. Clin
Sci (Lond) 118: 641–55.
3. Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s
syndrome. Lancet 367: 1605–17.
4. Bergthorsdottir R, Leonsson-Zachrisson M, Ode´n A, Johannsson G (2006)
Premature mortality in patients with Addison’s disease: a population-based
study. J Clin Endocrinol Metab 91: 4849–53.
5. van der Sluis RJ, van Puijvelde GH, Van Berkel TJ, Hoekstra M (2012)
Adrenalectomy stimulates the formation of initial atherosclerotic lesions: reversal
by adrenal transplantation. Atherosclerosis 221: 76–83.
6. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, et al.
(2007) Mortality in patients treated for Cushing’s disease is increased, compared
with patients treated for nonfunctioning pituitary macroadenoma. J Clin
Endocrinol Metab 92: 976–81.
7. Oppenheim E, Bruger M (1952) Experimental cholesterol atherosclerosis. XI
Studies with Vitamin A. AMA Arch Pathol 53: 520–2.
8. Gordon D, Kobernick SD, McMillan GC, Duff GL (1954) The effect of
cortisone on the serum lipids and on the development of experimental
cholesterol atherosclerosis in the rabbit. J Exp Med 99: 371–86.
9. Bailey JM, Butler J (1985) Anti-inflammatory drugs in experimental atheroscle-
rosis. Part 6. Combination therapy with steroid and non-steroid agents.
Atherosclerosis 54: 205–12.
10. Naito M, Yasue M, Asai K, Yamada K, Hayashi T, et al. (1992) Effects of
dexamethasone on experimental atherosclerosis in cholesterol-fed rabbits. J Nutr
Sci Vitaminol (Tokyo) 38: 255–64.
11. Asai K, Funaki C, Hayashi T, Yamada K, Naito M, et al. (1993)
Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed
rabbits. Possible mechanisms. Arterioscler Thromb 13: 892–9.
12. Strecker EP, Gabelmann A, Boos I, Lucas C, Xu Z, et al. (1998) Effect on
intimal hyperplasia of dexamethasone released from coated metal stents
compared with non-coated stents in canine femoral arteries. Cardiovasc
Intervent Radiol 21: 487–96.
13. Deuchar GA, McLean D, Hadoke PW, Brownstein DG, Webb DJ, et al. (2011)
11b-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis
and causes proinflammatory changes in the endothelium in apoe2/2 mice.
Endocrinology 152: 236–46.
14. Kumari M, Grahame-Clarke C, Shanks N, Marmot M, Lightman S, et al.
(2003) Chronic stress accelerates atherosclerosis in the apolipoprotein E deficient
mouse. Stress 6: 297–9.
15. Bernberg E, Andersson IJ, Gan LM, Naylor AS, Johansson ME, et al. (2008)
Effects of social isolation and environmental enrichment on atherosclerosis in
ApoE2/2 mice. Stress 11: 381–9.
16. Bernberg E, Andersson IJ, Tidstrand S, Johansson ME, Bergstro¨m G, et al.
(2009) Repeated exposure to stressors do not accelerate atherosclerosis in
ApoE2/2 mice. Atherosclerosis 204: 90–5.
17. de Kloet ER, Joe¨ls M, Holsboer F (2005) Stress and the brain: from adaptation
to disease. Nat Rev Neurosci 6: 463–75.
18. Laskowitz DT, Lee DM, Schmechel D, Staats HF (2000) Altered immune
responses in apolipoprotein E-deficient mice. J Lipid Res 41: 613–20.
19. de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie
GM, et al. (2008) Atorvastatin increases HDL cholesterol by reducing CETP
expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 197:
57–63.
20. van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie
GM, et al. (2007) Fenofibrate increases HDL-cholesterol by reducing cholesteryl
ester transfer protein expression. J Lipid Res 48: 1763–71.
21. de Haan W, de Vries-van der Weij J, van der Hoorn JW, Gautier T, van der
Hoogt CC, et al. (2008) Torcetrapib does not reduce atherosclerosis beyond
atorvastatin and induces more proinflammatory lesions than atorvastatin.
Circulation 117: 2515–22.
22. van der Hoorn JW, de Haan W, Berbe´e JF, Havekes LM, Jukema JW, et al.
(2008) Niacin increases HDL by reducing hepatic expression and plasma levels
of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler
Thromb Vasc Biol 28: 2016–22.
23. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der
Hoorn J, et al. (2007) Mouse models for atherosclerosis and p harmaceutical
modifiers. Arterioscler Thromb Vasc Biol 27: 1706–21.
24. Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie
GM, et al. (2006) Cholesteryl ester transfer protein decreases high-density
lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
Arterioscler Thromb Vasc Biol 26: 2552–9.
25. Karatsoreos IN, Bhagat SM, Bowles NP, Weil ZM, Pfaff DW, et al. (2010)
Endocrine and physiological changes in response to chronic corticosterone: a
potential model of the metabolic syndrome in mouse. Endocrinology 151: 2117–
27.
26. Dalm S, Brinks V, van der Mark MH, de Kloet ER, Oitzl MS, et al. (2008) Non-
invasive stress-free application of glucocorticoid ligands in mice. J Neurosci
Methods 170: 77–84.
27. Mather K (2009) Surrogate measures of insulin resistance: of rats, mice, and
men. Am J Physiol Endocrinol Metab 296: E398–9.
Figure 4. Effect of transient and continuous CORT treatment on atherosclerosis development: representative HPS-stained pictures
of lesions (A), lesion area (B), lesion type as % of the total lesion (C), representative pictures of monocyte/macrophage staining
(adhering monocytes shown by arrows) (D), adhering monocytes per segment (E), macrophage content of the plaque (F) and
macrophages as % of the lesion area (G). Serum anti-ox-LDL specific antibodies (H) and serum M-CSF (I) were measured on week 17. (Control
group: white bars, transient group: grey bars and continuous group: black bars). Data are means6 SEM (n= 17–21), Anova with Tukey’s post-hoc test,
*#P,0.05, **P,0.01, *versus control group and #versus transient group.
doi:10.1371/journal.pone.0063882.g004
High CORT and Atherosclerosis in E3L.CETP Mice
PLOS ONE | www.plosone.org 9 May 2013 | Volume 8 | Issue 5 | e63882
28. Gijbels MJ, van der Cammen M, van der Laan LJ, Emeis JJ, Havekes LM, et al.
(1999) Progression and regression of atherosclerosis in APOE3-Leiden
transgenic mice: an immunohistochemical study. Atherosclerosis 143: 15–25.
29. Volger OL, Mensink RP, Plat J, Hornstra G, Havekes LM, et al. (2001) Dietary
vegetable oil and wood derived plant stanol esters reduce atherosclerotic lesion
size and severity in apoE*3-Leiden transgenic mice. Atherosclerosis 157: 375–
81.
30. Hume DA (2006) The mononuclear phagocyte system. Curr Opin Immunol. 18:
49–53.
31. Roelfsema F, Pincus SM, Veldhuis JD (1998) Patients with Cushing’s disease
secrete adrenocorticotropin and cortisol jointly more asynchronously than
healthy subjects. J Clin Endocrinol Metab. 83: 688–92.
32. Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH (2007)
Atherosclerosis and liver inflammation induced by increased dietary cholesterol
intake: a combined transcriptomics and metabolomics analysis. Genome Biol 8:
R200.
33. Ku¨hnast S, van der Hoorn JW, van den Hoek AM, Havekes LM, Liau G, et al.
(2012) Aliskiren inhibits atherosclerosis development and improves plaque
stability in APOE*3Leiden.CETP transgenic mice with or without treatment
with atorvastatin. J Hypertens 30: 107–16.
34. Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s
disease: clinical and health-related quality of life aspects. Eur J Endocrinol.167:
311–26.
35. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G, et al. (2004) High
cardiovascular risk in patients with Cushing’s syndrome according to 1999
WHO/ISH guidelines. Clin Endocrinol (Oxf). 61: 768–77.
36. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, et al. (1999) Persistence
of increased cardiovascular risk in patients with Cushing’s disease after five years
of successful cure. J Clin Endocrinol Metab 84: 2664–72.
37. Biddie SC, John S, Hager GL (2010) Genome-wide mechanisms of nuclear
receptor action. Trends Endocrinol Metab 21: 3–9.
38. Lee RS, Tamashiro KL, Yang X, Purcell RH, Harvey A, et al. (2010) Chronic
corticosterone exposure increases expression and decreases deoxyribonucleic
acid methylation of Fkbp5 in mice. Endocrinology 151: 4332–43.
39. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease.
N Engl J Med 352: 1685–95.
40. Frostega˚rd J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, et al. (1999)
Cytokine expression in advanced human atherosclerotic plaques: dominance of
pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis
145: 33–43.
41. Yamada K, Naito M, Hayashi T, Asai K, Yoshimine N, et al. (1993) Effects of
dexamethasone on migration of human monocytes in response to oxidized beta-
very low density lipoprotein. Artery 20: 253–67.
42. Wheller SK, Perretti M (1997) Dexamethasone inhibits cytokine-induced
intercellular adhesion molecule-1 up-regulation on endothelial cell lines.
Eur J Pharmacol 331: 65–71.
43. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, et al. (2008) Functional
mineralocorticoid receptors in human vascular endothelial cells regulate
intercellular adhesion molecule-1 expression and promote leukocyte adhesion.
Circ Res 102: 1359–67.
44. Garcı´a RA, Search DJ, Lupisella JA, Ostrowski J, Guan B, et al. (2013) 11b-
Hydroxysteroid Dehydrogenase Type 1 Gene Knockout Attenuates Atheroscle-
rosis and In Vivo Foam Cell Formation in Hyperlipidemic apoE(2/2) Mice.
PLoS One 8: e53192.
45. Popova A, Kzhyshkowska J, Nurgazieva D, Goerdt S, Gratchev A, et al (2011)
Pro- and anti-inflammatory control of M-CSF-mediated macrophage differen-
tiation. Immunobiology 216: 164–72.
46. Sakai M, Biwa T, Matsumura T, Takemura T, Matsuda H, et al. (1999)
Glucocorticoid inhibits oxidized LDL-induced macrophage growth by suppress-
ing the expression of granulocyte/macrophage colony-stimulating factor.
Arterioscler Thromb Vasc Biol 19: 1726–33.
47. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, et al. (2003)
Diagnosis and complications of Cushing’s syndrome: a consensus statement.
J Clin Endocrinol Metab 88: 5593–602.
48. van Raalte DH, Ouwens DM, Diamant M (2009) Novel insights into
glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic
options? Eur J Clin Invest 39: 81–93.
49. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, et al. (2003)
Cardiovascular risk factors and common carotid artery caliber and stiffness in
patients with Cushing’s disease during active disease and 1 year after disease
remission. J Clin Endocrinol Metab 88: 2527–33.
50. Albiger N, Testa RM, Ferrari M, Bilora F, Petrobelli F, et al. (2003) Patients
with Cushing’s syndrome have increased intimal media thickness at different
vascular levels: comparison with a population matched for similar cardiovascular
risk factors. Horm Metab Res 38: 405–10.
51. Geer EB, Shen W, Strohmayer E, Post KD, Freda PU, et al. (2012) Body
composition and cardiovascular risk markers after remission of Cushing’s
disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab
97: 1702–11.
52. van der Pas R, de Bruin C, Leebeek FW, de Maat MP, Rijken DC, et al. (2012)
The hypercoagulable state in Cushing’s disease is associated with increased levels
of procoagulant factors and impaired fibrinolysis, but is not reversible after short-
term biochemical remission induced by medical therapy. J Clin Endocrinol
Metab 97: 1303–10.
53. Bell ME, Bhatnagar S, Liang J, Soriano L, Nagy TR, et al. (2000) Voluntary
sucrose ingestion, like corticosterone replacement, prevents the metabolic deficits
of adrenalectomy. J Neuroendocrinol 212: 461–4703.
54. Bhatnagar S, Bell ME, Soriano L, Nagy TR, Dallman MF, et al. (2000)
Corticosterone facilitates saccharin intake in adrenalectomized rats. Does
corticosterone increase stimulus salience? J Neuroendocrinol 12: 453–60.
55. la Fleur SE, Akana SF, Manalo S, Dallman MF (2004) Interaction between
corticosterone and insulin in obesity: regulation of lard intake and fat stores.
Endocrinology 145: 2174–85.
56. Warne JP, Akana SF, Ginsberg AB, Horneman HF, Pecoraro NC, et al. (2009)
Disengaging insulin from corticosterone: roles of each on energy intake and
disposition. Am J Physiol Regul Integr Comp Physiol 296: R1366–75.
57. Gounarides JS, Korach-Andre´ M, Killary K, Argentieri G, Turner O, et al.
(2008) Effect of dexamethasone on glucose tolerance and fat metabolism in a
diet-induced obesity mouse model. Endocrinology 149: 758–66.
58. Resmini E, Farkas C, Murillo B, Barahona MJ, Santos A, et al. (2010) Body
composition after endogenous (Cushing’s syndrome) and exogenous (rheumatoid
arthritis) exposure to glucocorticoids. Horm Metab Res 42: 613–8.
59. Pasquali R, Vicennati V, Cacciari M, Pagotto U (2006) The hypothalamic-
pituitary-adrenal axis activity in obesity and the metabolic syndrome.
Ann N Y Acad Sci 1083: 111–28.
60. Giordano R, Picu A, Marinazzo E, D’Angelo V, Berardelli R, et al. (2011)
Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of
different aetiologies during active disease and 1 year after remission. Clin
Endocrinol (Oxf) 75: 354–60.
61. Barahona MJ, Sucunza N, Resmini E, Ferna´ndez-Real JM, Ricart W, et al.
(2009) Persistent body fat mass and inflammatory marker increases after long-
term cure of Cushing’s syndrome. J Clin Endocrinol Metab 94: 3365–71.
62. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003)
Obesity is associated with macrophage accumulation in adipose tissue. J Clin
Invest. 112: 1796–808.
High CORT and Atherosclerosis in E3L.CETP Mice
PLOS ONE | www.plosone.org 10 May 2013 | Volume 8 | Issue 5 | e63882
